Logo image of LOVE.CA

CANNARA BIOTECH INC (LOVE.CA) Stock Fundamental Analysis

TSX-V:LOVE - TSX Venture Exchange - CA13765U2002 - Common Stock - Currency: CAD

1.2  0 (0%)

Fundamental Rating

4

Overall LOVE gets a fundamental rating of 4 out of 10. We evaluated LOVE against 4 industry peers in the Personal Care Products industry. LOVE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LOVE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

LOVE had positive earnings in the past year.
LOVE had a positive operating cash flow in the past year.
In multiple years LOVE reported negative net income over the last 5 years.
In multiple years LOVE reported negative operating cash flow during the last 5 years.
LOVE.CA Yearly Net Income VS EBIT VS OCF VS FCFLOVE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

LOVE has a Return On Assets of 8.30%. This is amongst the best in the industry. LOVE outperforms 100.00% of its industry peers.
LOVE has a better Return On Equity (14.22%) than 100.00% of its industry peers.
Industry RankSector Rank
ROA 8.3%
ROE 14.22%
ROIC N/A
ROA(3y)3.63%
ROA(5y)-2.7%
ROE(3y)6.49%
ROE(5y)-3.09%
ROIC(3y)N/A
ROIC(5y)N/A
LOVE.CA Yearly ROA, ROE, ROICLOVE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

LOVE has a Profit Margin of 14.16%. This is amongst the best in the industry. LOVE outperforms 100.00% of its industry peers.
Looking at the Gross Margin, with a value of 9.96%, LOVE is doing worse than 75.00% of the companies in the same industry.
In the last couple of years the Gross Margin of LOVE has declined.
Industry RankSector Rank
OM N/A
PM (TTM) 14.16%
GM 9.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-40.07%
GM growth 5Y-41.26%
LOVE.CA Yearly Profit, Operating, Gross MarginsLOVE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

5

2. Health

2.1 Basic Checks

LOVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LOVE has been reduced compared to 1 year ago.
The number of shares outstanding for LOVE has been increased compared to 5 years ago.
The debt/assets ratio for LOVE has been reduced compared to a year ago.
LOVE.CA Yearly Shares OutstandingLOVE.CA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
LOVE.CA Yearly Total Debt VS Total AssetsLOVE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

LOVE has an Altman-Z score of 1.54. This is a bad value and indicates that LOVE is not financially healthy and even has some risk of bankruptcy.
LOVE has a Altman-Z score of 1.54. This is in the better half of the industry: LOVE outperforms 75.00% of its industry peers.
LOVE has a debt to FCF ratio of 8.39. This is a slightly negative value and a sign of low solvency as LOVE would need 8.39 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 8.39, LOVE is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
A Debt/Equity ratio of 0.43 indicates that LOVE is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.43, LOVE belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF 8.39
Altman-Z 1.54
ROIC/WACCN/A
WACC6.82%
LOVE.CA Yearly LT Debt VS Equity VS FCFLOVE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 2.35 indicates that LOVE has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.35, LOVE is doing good in the industry, outperforming 75.00% of the companies in the same industry.
A Quick Ratio of 0.93 indicates that LOVE may have some problems paying its short term obligations.
LOVE's Quick ratio of 0.93 is fine compared to the rest of the industry. LOVE outperforms 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 0.93
LOVE.CA Yearly Current Assets VS Current LiabilitesLOVE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

4

3. Growth

3.1 Past

LOVE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 110.22%, which is quite impressive.
LOVE shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.97%.
LOVE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 108.26% yearly.
EPS 1Y (TTM)110.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%193.73%
Revenue 1Y (TTM)28.97%
Revenue growth 3Y68.19%
Revenue growth 5Y108.26%
Sales Q2Q%35.07%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LOVE.CA Yearly Revenue VS EstimatesLOVE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 8.00, the valuation of LOVE can be described as reasonable.
Based on the Price/Earnings ratio, LOVE is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.55. LOVE is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 8
Fwd PE N/A
LOVE.CA Price Earnings VS Forward Price EarningsLOVE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, LOVE is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 18.85
EV/EBITDA N/A
LOVE.CA Per share dataLOVE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

LOVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CANNARA BIOTECH INC

TSX-V:LOVE (6/6/2025, 7:00:00 PM)

1.2

0 (0%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)04-28 2025-04-28
Earnings (Next)07-25 2025-07-25
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners27.69%
Ins Owner ChangeN/A
Market Cap109.72M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 8
Fwd PE N/A
P/S 1.16
P/FCF 18.85
P/OCF 9.73
P/B 1.16
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)0.15
EY12.5%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.06
FCFY5.31%
OCF(TTM)0.12
OCFY10.28%
SpS1.04
BVpS1.03
TBVpS1.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 8.3%
ROE 14.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14.16%
GM 9.96%
FCFM 6.15%
ROA(3y)3.63%
ROA(5y)-2.7%
ROE(3y)6.49%
ROE(5y)-3.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-40.07%
GM growth 5Y-41.26%
F-Score5
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF 8.39
Debt/EBITDA N/A
Cap/Depr 84.34%
Cap/Sales 5.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 43.44%
Current Ratio 2.35
Quick Ratio 0.93
Altman-Z 1.54
F-Score5
WACC6.82%
ROIC/WACCN/A
Cap/Depr(3y)228.25%
Cap/Depr(5y)410.31%
Cap/Sales(3y)22.24%
Cap/Sales(5y)120%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)110.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%193.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)28.97%
Revenue growth 3Y68.19%
Revenue growth 5Y108.26%
Sales Q2Q%35.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y132.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y334.7%
OCF growth 3YN/A
OCF growth 5YN/A